Is Anbio Biotechnology (NNNN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 1.2% / 30% | 0.1% / 30% | 4.12% / 5% | ✓ HALAL |
| DJIM | 0.0% / 33% | 1.2% / 33% | 0.1% / 33% | 4.12% / 5% | ✓ HALAL |
| MSCI | 0.0% / 33% | 62.2% / 33% | 5.6% / 33% | 4.12% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 1.2% / 33% | 0.1% / 33% | 4.12% / 5% | ✓ HALAL |
| FTSE | 0.0% / 33% | 62.2% / 33% | 5.6% / 50% | 4.12% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 89.7% | |
| Operating Margin | 73.4% | |
| Net Margin | 37.2% | |
| Return on Equity (ROE) | 11.2% | |
| Return on Assets (ROA) | 4.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $2M |
| Free Cash Flow | $2M |
| Current Ratio | 211.1 |
| Total Assets | $19M |
Price & Trading
| Last Close | $23.43 |
| 50-Day MA | $24.57 |
| 200-Day MA | $32.08 |
| Avg Volume | 59K |
|
52-Week Range
$5.89
| |
About Anbio Biotechnology (NNNN)
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Purification Calculator
As a halal stock with 4.12% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Anbio Biotechnology (NNNN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Anbio Biotechnology is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Anbio Biotechnology's debt ratio?
Anbio Biotechnology's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
Does Anbio Biotechnology require dividend purification?
Yes, Anbio Biotechnology has an impermissible income ratio of 4.12%, which means 4.12% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Anbio Biotechnology's key financial metrics?
Anbio Biotechnology has a market capitalization of $1.0B, trailing P/E ratio of 398.7, and revenue of $8M. The company maintains a gross margin of 89.7% and a net margin of 37.2%. Return on equity stands at 11.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.